_________________________
DELAWARE BIO
EVENTS ____________________
|
|
THURSDAY, NOV. 12
Delaware Biotechnology Institute
15 Innovation Way, Newark, DE.
7:30 a.m. - 9:00 a.m.
_________________________
OTHER UPCOMING
EVENTS ____________________
OCTOBER 1
15 Innovation Way
Newark, DE 19711
9:00 a.m. - 5:00 p.m.
___________________
OCTOBER 1
100 David Hollowell Drive
Newark, DE 19716
8:00 - 6:00 p.m.
___________________
OCTOBER 11 - 14
New Cells for New Vaccines IV
Hotel du Pont
11th & Market Streets
Wilmington, DE 19801
___________________
NOVEMBER 4
Calibration & Validation Clinic
Hosted by VWR
15 Innovation Way
Newark, DE 19711
12:00 - 2:30 p.m.
___________________
NOVEMBER 16 - 17
Biotech 2009
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107
___________________
|
|
|
|
MEMBER SPOTLIGHT
___________ |
Vial-ette 4 U - One Solution For all Your Reagents & Samples Handling
Multi-purpose Cryovial & Microtube Holder (Package, Storage and Bench Work)
- Easy One-Handed Operation -Thumb Push to Open
- Bench or Ice Bath Standing
- Stable and Secure Loading
The Vial-ette 4 U micro-tube storage rack system from Occam Biolabs is desgined to house 0.2ml PCR tubes and strips, 0.5-2.0ml microtubes, 0.5-2.0ml cryovials, 0.5-1.4ml Microtiter tubes, 0.1-2.0ml autosampler vials. It is ideal to store and transport reagents.
The Vial-ette 4 U offers unique advantages over traditional packages, such as easy one-handed operation and stable, secure pipetiting. It also has space-saving, cost-effective and environment-friendly features.
If interested, please contact Adrienne Ferrell at adrienne.ferrell@obiolabs.com
or visit our website at www.obiolabs.com
|
|
Creative Communications is your guide to creating commitment to action through communications.
We have a proven methodology that achieves the results your company needs. We provide a full range of marketing, employee and strategic communications services through a unique blend of expertise and creativity. Our services address communications for change in the areas of organization effectiveness, public and community relations and marketing.
Established in 1993, Creative Communications is an award-winning certified Women Business Enterprise (WBE) serving a variety of clients including corporations, privately held firms, nonprofit organizations, and government entities. Whether the need is for one communication tool or a complete communications campaign, Creative Communications has the resources to work creatively and within budget, managing each project from concept to implementation and measuring success.
Travel our website to learn how Creative Communications can help your organization achieve results through commitment to action.
| |
|
|
|
AstraZeneca joins anti-cancer project
AstraZeneca, the UK's second largest pharmaceutical group, has invested £4m into a three-year joint venture to develop new anti-cancer drugs.
By Jamie Dunkley Published: 07 Jun 2009
AstraZeneca
The blue-chip company will work alongside Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) to target "molecular chaperones", which support the growth of cancer cells.
As part of the deal, the ICR will lead the scientific work using £1.6m from Cancer Research UK, while AstraZeneca will sell the compounds developed during the collaboration. CRT and the ICR will receive upfront payments as well as milestone payments and royalties on any future sales from the work.
Dr Les Hughes, AstraZeneca vice-president of cancer and infection research, said: "We are impressed by the potential in these targets and are delighted to be joining forces with this world-renowned research team to progress this work. Drawing on our long history of discovering and developing cancer therapeutics, we aim to convert this early scientific promise into treatments that could make a real impact on the lives of cancer patients."
Molecular chaperones help newly made proteins function correctly and also, under normal conditions, help cells to respond to stress. However, new research suggests that these same molecular chaperones contribute to the activity of cancer-causing proteins and help cancer cells to survive and become more aggressive.
Dr Phil L'Huillier, an executive at CRT, said: "Time will tell if these potential targets will become workable treatments, but this work shows great promise."
| |
|
|
|
